Monopar Therapeutics announced that its abstract titled “Evaluation of Anti-uPAR Antibody as a Radiopharmaceutical for Imaging and Treatment of Solid Tumors” has been accepted as a “Top-Rated Oral Presentation” within the Scientific Program of the European Association of Nuclear Medicine 2024 Annual Congress to be held on October 19-23, 2024 in Hamburg, Germany. Monopar’s abstract details its MNPR-101-RIT, a novel first-in-class radio-immuno-therapeutic program that targets cancer expressing the urokinase plasminogen activator receptor, including triple-negative breast, colorectal, and pancreatic cancers. The Company’s preclinical data demonstrate compelling and durable anti-tumor benefits with MNPR-101 conjugated to therapeutic radioisotopes, including lutetium-177 and actinium-225. Monopar recently initiated its MNPR-101-Zr first-in-human Phase 1 imaging and dosimetry clinical trial in advanced cancer patients.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
- Monopar Therapeutics Enhances Alliance with NorthStar Medical
- Monopar and NorthStar Amend & Extend Collaboration
- Monopar Therapeutics, NorthStar Medical amend, extend collaboration
- Monopar Therapeutics Showcases MNPR-101-Zr Progress at SNMMI